Report: Employer Branding: What Matters to Life Sciences Candidates
Post Content
Report: Employer Branding: What Matters to Life Sciences Candidates Read More »
Uncategorized
5 steps to navigate the FDA’s new lab developed test rule
Laboratories face a series of upcoming deadlines to comply with stricter FDA oversight of in-house tests. Here are five strategies labs can take to be ready.
5 steps to navigate the FDA’s new lab developed test rule Read More »
Senate report slams Medicare Advantage insurers for using predictive technology to deny claims
UnitedHealth, CVS and Humana used technology to increase MA prior authorization denials for post-acute services, boosting profits, according to a report from a Senate subcommittee.
Boston Scientific wins FDA approval for Farapulse cardiac mapping
Stifel analyst Rick Wise said Boston Scientific can now offer “one-stop-shopping” with a pulsed field ablation catheter and integrated mapping system to treat atrial fibrillation.
Boston Scientific wins FDA approval for Farapulse cardiac mapping Read More »
Humana sues HHS over calamitous Medicare Advantage star ratings decrease
It’s the latest in a string of lawsuits from health insurers scrambling to protect their prized quality scores and the money those ratings represent.
Humana sues HHS over calamitous Medicare Advantage star ratings decrease Read More »
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion Read More »
Seaport, Six Months Out of Stealth, Comes Back for $225M Raise
Seaport Therapeutics, kick started by the former leaders of Karuna Therapeutics, has raised $225 million in an oversubscribed Series B to fund a pipeline of neuropsychiatric medicines.
Seaport, Six Months Out of Stealth, Comes Back for $225M Raise Read More »
Lykos Announces ‘Productive’ Meeting With FDA Regarding Rejected MDMA Drug
In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next steps for the embattled program, following the FDA’s rejection in August 2024.
Lykos Announces ‘Productive’ Meeting With FDA Regarding Rejected MDMA Drug Read More »
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit Read More »
USP Aims to Double, Diversify Volunteer Applicant Pool for 2025–2030 Cycle
United States Pharmacopeia is recruiting expert volunteers from academia, industry, regulatory and healthcare to develop, revise and approve medicine, dietary supplement and food ingredient standards and solutions used in more than 150 countries to improve global public health. The volunteers will serve from 2025 to 2030.
USP Aims to Double, Diversify Volunteer Applicant Pool for 2025–2030 Cycle Read More »